Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 8 points (0.1%) at 15,256 as of Monday, June 10, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,353 issues advancing vs. 1,578 declining with 107 unchanged. The Drugs industry currently sits up 0.5% versus the S&P 500, which is up 0.1%. A company within the industry that increased today was Novo Nordisk A/S ( NVO), up 0.75. On the negative front, top decliners within the industry include Dynavax Technologies Corporation ( DVAX), down 35.63, and Alexion Pharmaceuticals ( ALXN), down 1.75. TheStreet Ratings group would like to highlight 5 stocks pushing the industry higher today: 5. ACADIA Pharmaceuticals ( ACAD) is one of the companies pushing the Drugs industry higher today. As of noon trading, ACADIA Pharmaceuticals is up $2.91 (17.11) to $19.92 on heavy volume Thus far, 9.1 million shares of ACADIA Pharmaceuticals exchanged hands as compared to its average daily volume of 4.2 million shares. The stock has ranged in price between $17.05-$20.09 after having opened the day at $17.29 as compared to the previous trading day's close of $17.01. ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. ACADIA Pharmaceuticals has a market cap of $1.5 billion and is part of the health care sector. Shares are up 256.3% year to date as of the close of trading on Friday. Currently there are 8 analysts that rate ACADIA Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold. TheStreet Ratings rates ACADIA Pharmaceuticals as a sell. Among the areas we feel are negative, one of the most important has been weak operating cash flow. Get the full ACADIA Pharmaceuticals Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.